secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0000950170-24-114841
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics receives FDA IND clearance for CLN-978 in moderate-to-severe SLE
--------------------------------------------------------------------------------

- FDA cleared IND for CLN-978, a CD19 T cell engager, in systemic lupus erythematosus.
- Phase 1 trial will enroll patients with SLEDAI score ≥8 and inadequate response to ≥2 prior treatments.
- Starting dose 10 mcg; Part A dose escalation, Part B dose expansion with multiple schedules.
- First development-stage CD19 T cell engager to receive FDA IND clearance in autoimmune diseases.
- Global trial already cleared in Australia (NCT06613360); U.S. enrollment now allowed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024114841/0000950170-24-114841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024114841/cgem-20241016.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-114841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer